These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 29675620

  • 1. Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.
    Castelli R, Schiavon R, Rossi V, Deliliers GL.
    Med Oncol; 2018 Apr 19; 35(5):76. PubMed ID: 29675620
    [Abstract] [Full Text] [Related]

  • 2. Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.
    Hattakitpanitchakul S, Kobbuaklee S, Wudhikarn K, Polprasert C.
    Asian Pac J Cancer Prev; 2021 Dec 01; 22(12):4037-4042. PubMed ID: 34967586
    [Abstract] [Full Text] [Related]

  • 3. Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
    Kelaidi C, Fenaux P.
    Expert Opin Biol Ther; 2010 Apr 01; 10(4):605-14. PubMed ID: 20201708
    [Abstract] [Full Text] [Related]

  • 4. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
    Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P.
    J Clin Oncol; 2017 May 10; 35(14):1591-1597. PubMed ID: 28350519
    [Abstract] [Full Text] [Related]

  • 5. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E, Rossi E, Clavio M, Congiu A, Gobbi M, Grosso M, Secondo V, Spriano M, Timitilli S, Ghio R.
    Ann Hematol; 2006 Mar 10; 85(3):174-80. PubMed ID: 16408206
    [Abstract] [Full Text] [Related]

  • 6. Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols.
    Gascón P, Krendyukov A, Mathieson N, Aapro M.
    Leuk Res; 2019 Jun 10; 81():35-42. PubMed ID: 31005849
    [Abstract] [Full Text] [Related]

  • 7. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.
    Villegas A, Arrizabalaga B, Fernández-Lago C, Castro M, Mayans JR, González-Porras JR, Duarte RF, Remacha AF, Luño E, Gasquet JA.
    Curr Med Res Opin; 2011 May 10; 27(5):951-60. PubMed ID: 21381892
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes.
    Giraldo P, Nomdedeu B, Loscertales J, Requena C, de Paz R, Tormo M, Navarro P, Benedit P, Gasquet JA, Aranesp in Myelodysplastic Syndromes (ARM) Study Group.
    Cancer; 2006 Dec 15; 107(12):2807-16. PubMed ID: 17115424
    [Abstract] [Full Text] [Related]

  • 10. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes.
    Santini V.
    Oncologist; 2011 Dec 15; 16 Suppl 3():35-42. PubMed ID: 21930833
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors.
    Mies A, Platzbecker U.
    Semin Hematol; 2017 Jul 15; 54(3):141-146. PubMed ID: 28958287
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
    Park S, Kelaidi C, Meunier M, Casadevall N, Gerds AT, Platzbecker U.
    Ann Hematol; 2020 Jan 15; 99(1):7-19. PubMed ID: 31650290
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.
    Houston BL, Jayakar J, Wells RA, Lenis M, Zhang L, Zhu N, Leitch HA, Nevill TJ, Yee KWL, Leber B, Sabloff M, St-Hilaire E, Kumar R, Geddes M, Shamy A, Storring JM, Keating MM, Elemary M, Delage R, Mamedov A, Buckstein R.
    Ann Hematol; 2017 Dec 15; 96(12):2025-2029. PubMed ID: 28975386
    [Abstract] [Full Text] [Related]

  • 20. The fraction of CD117/c-KIT-expressing erythroid precursors predicts ESA response in low-risk myelodysplastic syndromes.
    Raimbault A, Itzykson R, Willems L, Rousseau A, Chapuis N, Mathis S, Clauser S, Radford-Weiss I, Bouscary D, Fontenay M, Kosmider O, Bardet V.
    Cytometry B Clin Cytom; 2019 May 15; 96(3):215-222. PubMed ID: 30963682
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.